SLondon, UK – October 7, 2025 – AstraZeneca announced that Baxdrostat met the primary endpoint in the Bax24 Phase III trial, demonstrating a statistically significant and highly clinically meaningful reduction in 24-hour ambulatory systolic blood pressure (SBP) compared with placebo in patients with treatment-resistant hypertension (rHTN). The positive results confirm Baxdrostat’s potential as a novel therapy for patients whose blood pressure remains uncontrolled despite current treatments.
Science SignificanceAVB-114
Baxdrostat is a first-in-class, selective oral inhibitor of aldosterone synthase (CYP11B2), the enzyme responsible for aldosterone production. By targeting aldosterone, a hormone that contributes to sodium retention and elevated blood pressure, Baxdrostat offers a unique approach to controlling hard-to-treat hypertension. In the Bax24 trial, 218 patients with rHTN received 2mg of Baxdrostat or placebo once daily for 12 weeks on top of standard-of-care therapy. The trial demonstrated a significant reduction in 24-hour average systolic blood pressure, including during the critical early morning period, when hypertensive patients face elevated cardiovascular risk. Consistent 24-hour blood pressure control is recognized as a stronger predictor of cardiovascular events than clinic-based measurements, and Baxdrostat’s durable half-life of 26–30 hours ensure prolonged efficacy. These findings reinforce its potential to improve outcomes in high-risk patients, including those prone to morning surges in blood pressure that are linked to heart attacks, strokes, and cardiovascular mortality.
Regulatory Significance
With Baxdrostat demonstrating robust efficacy and a favorable safety profile, AstraZeneca is advancing regulatory filings globally. Data from Bax24 will be shared with regulatory authorities and presented in a late-breaking session at the American Heart Association (AHA) Scientific Sessions in November 2025. The trial followed a randomized, double-blind, placebo-controlled design, and secondary endpoints evaluated daytime and nighttime SBP, nocturnal dipping, and the proportion of patients achieving 24-hour SBP <130 mmHg. The strong efficacy signal, coupled with consistent tolerability, strengthens the case for regulatory approval for both monotherapy and combination therapy indications, including primary aldosteronism, chronic kidney disease (CKD), and heart failure prevention.
Business Significance
Advertisement
Baxdrostat represents a strategic asset in AstraZeneca’s Cardiovascular, Renal, and Metabolism (CVRM) portfolio, one of the company’s key growth areas. AstraZeneca acquired Baxdrostat through its 2023 acquisition of CinCor Pharma, reinforcing its position in hypertension and cardiorenal disease. The successful Phase III readout positions Baxdrostat for global commercialization as a differentiated therapy for patients with resistant hypertension—a population with high unmet medical need. AstraZeneca’s investment in CVRM leverages a science-led approach to understanding interconnections between the heart, kidneys, liver, and pancreas, with the goal of protecting organs, slowing disease progression, and eventually enabling regenerative medicine approaches.
Patients’ Significance
Hypertension affects 1.4 billion people worldwide, with approximately 50% of U.S. patients on multiple treatments failing to achieve blood pressure control. rHTN, defined as uncontrolled blood pressure despite three or more medications, is associated with a markedly increased risk of cardiovascular events and kidney disease. Baxdrostat’s 24-hour blood pressure control, including during early morning periods, directly addresses the elevated cardiovascular risk in this population. Its oral, once-daily regimen and selective mechanism offer patients a potentially safer and more effective treatment alternative, which could reduce heart attack, stroke, and mortality risks, improving both quality and duration of life.
Policy Significance
The Bax24 trial underscores the public health importance of innovative therapies targeting resistant hypertension, a condition with substantial societal and economic burden. Hard-to-control hypertension drives high rates of cardiovascular morbidity and mortality, and therapies like Baxdrostat can support policy initiatives focused on chronic disease management and preventive cardiovascular care. Global health authorities increasingly emphasize ambulatory blood pressure as a key clinical endpoint, recognizing its predictive power for cardiovascular outcomes. Positive Phase III results like Baxdrostat’s are likely to inform treatment guidelines and reimbursement policies, shaping access to therapies for high-risk hypertensive populations.
Transaction Highlights
Baxdrostat, acquired by AstraZeneca through its 2023 purchase of CinCor Pharma, has successfully met the primary endpoint in the Bax24 Phase III trial, demonstrating a statistically significant reduction in 24-hour ambulatory systolic blood pressure compared with placebo. The trial enrolled 218 patients with treatment-resistant hypertension, who received 2mg of Baxdrostat or placebo once daily for 12 weeks on top of standard-of-care therapy. Efficacy was observed throughout the 24-hour period, including the early morning, when patients are at highest risk of cardiovascular events, and the therapy was well tolerated, with a safety profile consistent with previous studies. The results advance Baxdrostat toward global regulatory submissions and future commercialization as both a monotherapy and combination therapy for hypertension, primary aldosteronism, chronic kidney disease, and heart failure prevention. Presentation of the data at the American Heart Association (AHA) Scientific Sessions in November 2025 will further support its clinical and regulatory profile, solidifying AstraZeneca’s strategic expansion in cardiovascular, renal, and metabolic disease (CVRM) therapies.
Source: AstraZeneca PLC Press Release
